Proposal to list laboratory equipment and consumables supplied by Olympus New Zealand Limited
PHARMAC is seeking feedback on a proposal to list a range of medical devices in Part III of Section H of the Pharmaceutical Schedule.
What we’re proposing
PHARMAC is seeking feedback on a proposal to list laboratory equipment and consumables supplied by Olympus New Zealand Limited (“Olympus”) in Part III of Section H of the Pharmaceutical Schedule from 1 August 2021 through a non-exclusive provisional agreement.
Consultation closes at 4pm Monday 5 July 2021 and feedback can be emailed to email@example.com.
What would the effect be?
From 1 August 2021 laboratory equipment and consumables supplied by Olympus would be listed under a proposed national agreement (“Agreement”) that all DHBs may purchase under, subject to consultation and approval by PHARMAC’s Board or delegate.
The Agreement would not be for sole supply and DHBs can continue to purchase other suppliers’ brands of laboratory equipment and consumables.
The Agreement would supersede any existing DHB agreements with Olympus for the medical devices included in the Agreement. Any medical device listed in the Agreement and purchased by a DHB would be in accordance with the terms and conditions, including price, stated in the Agreement effective from the date of listing in the Pharmaceutical Schedule.
Pricing for the laboratory equipment and consumables in the Agreement, subject to any prior termination of the Agreement, would not be increased without prior consultation and approval by PHARMAC.
Who we think will be interested
- DHB clinical staff in a range of different clinical settings including but not limited to:
- Clinical engineers and maintenance services
- Clinical product evaluators
- Laboratory managers, scientists, technicians and other laboratory staff
- Procurement officers and supply chain personnel
- Suppliers and wholesalers
About the medical devices
The laboratory equipment and consumables category includes medical devices used in the collection, receipt, preparation and analysis of human biological material for the purpose of supporting patient diagnosis, management and treatment.
Why we’re proposing this
The RFP was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
PHARMAC has been working with suppliers who responded to the RFP, and proposals were progressed to contract negotiation, to seek provisional agreements.
This proposal is the first agreement to arise from this process and we expect to consult on further provisional agreements with suppliers of laboratory equipment and consumables throughout 2021.
Details about our proposal
PHARMAC has entered into a provisional agreement with Olympus for the supply of laboratory equipment and consumables.
The proposal would result in Pharmaceutical Schedule listings for 128 laboratory equipment and consumable products being listed on the Pharmaceutical Schedule.
Further information, including pricing and contractual details, has been provided to DHB procurement personnel. Clinicians interested in further detail on what this means for their DHB should engage with their procurement teams.
Send us an email: firstname.lastname@example.org by 4pm Monday 5 July 2021.
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Your feedback may be shared
Feedback we receive is subject to the Official Information Act 1982 (OIA). Please be aware that we may need to share your feedback, including your identity, in response to an OIA request. This applies to anyone providing feedback, whether they are providing feedback themselves or for an organisation, in a personal or professional capacity.
We can only keep feedback confidential as allowed under the OIA and other related laws. If you want any part of your feedback treated as confidential, you need to tell us. Please let us know if you want to keep part of your feedback confidential, and why. Is it commercially sensitive, confidential or proprietary, or personal information? Clearly state this and tell us which parts of your feedback you want to keep confidential for these reasons. We will consider your request under our OIA requirements.